Dolichol-P-mannose Inhibitor Development Service

Dolichol-P-mannose Inhibitor Development Service

Dolichol-P-mannose (Dol-P-Man) Inhibitor Development Service at CD BioGlyco

Dol-P-Man is the mannose donor for glycosylphosphatidylinositol (GPI) mannosyltransferase reaction, which is an important intermediate product and has important functions within cells. Dol-P-Man is an esterified compound composed of phosphate esters of long-chain fatty alcohols (dolichol) and mannose. In the cytoplasm, glucose-6-phosphate is converted into mannose-6-phosphate through the action of a series of enzymes and then reacts with dolichol to form Dol-P-Man. It is then transferred to the endoplasmic reticulum (ER) chamber through specific transporters, where it serves as a substrate to participate in the protein glycosylation reaction and transfers the sugar group to the target protein. Based on this mechanism, CD BioGlyco provides professional Dol-P-Man inhibitor development services.

  • Inhibitor screening

CD BioGlyco has established a huge compound database, and we use efficient high-throughput screening (HTS) and computer-assisted technology to screen potential Dol-P-Man inhibitors.

  • Optimization and synthesis

CD BioGlyco conducts structure-activity relationship research on the initially screened Dol-P-Man inhibitors and provides chemical synthesis and structure optimization services based on the research results to improve their physical and chemical properties. At the same time, we provide purification and analysis for synthesized Dol-P-Man inhibitors.

  • Enzyme kinetic analysis

CD BioGlyco establishes a suitable experimental system to evaluate the inhibitory activity of Dol-P-Man against the enzyme. We purify or express a variety of Dol-P-Man enzymes, react the screened inhibitors with Dol-P-Man enzymes, and measure parameters such as their affinity to the enzyme, rate constant, and inhibition mechanism through appropriate detection methods to determine the best Dol-P-Man inhibitors. For example, 2-deoxy-2-amino-mannose inhibits α-1,2 mannosyltransferase, and a glucose analog (2-deoxy-2-fluoro-D-Glc) competitively binds to Dol-P-Man synthase, thereby blocking the normal synthesis process of Dol-P-Man.

  • Activity verification

CD BioGlyco also provides activity verification for Dol-P-Man inhibitors at the cellular level and in overall biological systems. We use cell and animal models to evaluate the biological activity, toxicity, and efficacy of Dol-P-Man inhibitors to determine their potential in disease treatment.

Fig.1 Dol-P-Man inhibitor development service. (CD BioGlyco)Fig.1 Dol-P-Man inhibitor development service. (CD BioGlyco)


Technology: Thin-layer chromatography

Journal: Journal of Biological Chemistry

IF: 4.8

Published: 1993

Results: The authors studied the effect of mannosamine (ManN) on the synthesis of GPI anchor precursors in mammalian cells. ManN inhibited the biosynthesis of Man3GPIs, whose structure was represented as H6, H7, and H8 from HeLa cells. HeLa cells were treated with different concentrations of ManN and labeled with [3H]Man. The results showed that a dose-dependent inhibition of the synthesis of Man3GPIs was detected. The authors believed that the peak between 14.5 and 15.2cm in the figure was Dol-P-Man, and the relative amount of the peak increased with increasing ManN concentration. Research showed that the inhibitory mechanism of ManN was the inhibition of α-1,2-mannosyltransferase.

Fig.2 Effect of ManN on GPI-anchored precursor synthesis in HeLa cells. (Sevlever & Rosenberry, 1993)Fig.2 Effect of ManN on GPI-anchored precursor synthesis in HeLa cells. (Sevlever & Rosenberry, 1993)


  • Anticancer drug development: Dol-P-Man is one of the substrates required in the N-glycosylation process. Developing inhibitors against Dol-P-Man interferes with the synthesis and utilization of this substrate, thereby affecting the glycosylation modification of specific proteins in tumor cells and exploring its potential as an anti-tumor drug.
  • Immunomodulator research: N-Glycosylation is one of the important immunomodulatory mechanisms. By inhibiting the synthesis or utilization of Dol-P-Man, the glycosylation level of specific proteins on the surface of immune cells is adjusted, affecting the activity and functions of immune cells, thereby studying the regulatory mechanism of immune responses.
  • Diabetes research: N-Glycosylation is closely related to metabolic diseases such as diabetes. By interfering with the synthesis or utilization of Dol-P-Man, the glycosylation modification of important proteins such as insulin receptors is regulated to further study metabolic regulation pathways and the pathogenesis of diabetes.


  • CD BioGlyco provides comprehensive Inhibitor Development Solutions covering the entire process from preliminary screening to in vivo efficacy evaluation to ensure the development of the most effective Dol-P-Man inhibitors.
  • CD BioGlyco uses advanced computational methods and HTS technology to quickly screen a large number of compounds to find potential candidate Dol-P-Man inhibitors.
  • CD BioGlyco performs efficient chemical synthesis and optimization to improve the synthesis yield and purity of Dol-P-Man inhibitors to meet subsequent research requirements.

CD BioGlyco utilizes diverse chemical libraries for HTS to discover superior compounds against Dol-P-Man. We will provide custom services based on client needs and flexibly respond to project requirements to achieve the best Dol-P-Man inhibitor development results. Please feel free to contact us for specific details if you require quality inhibitor development service.


  1. Brown, J.R.; et al. Glycan antagonists and inhibitors: a fount for drug discovery. Critical Reviews in Biochemistry and Molecular Biology. 2007, 42(6): 481-515.
  2. Sevlever, D.; Rosenberry, T.L. Mannosamine inhibits the synthesis of putative glycoinositol phospholipid anchor precursors in mammalian cells without incorporating into an accumulated intermediate. Journal of Biological Chemistry. 1993, 268(15): 10938-10945.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.